FindTrial
Sign In

To compare the outcome of two spinal drugs on patients in Percutaneous Nephrolithotomy

A Comparative Study to evaluate the efficacy between Ropivacaine 0.75% with Nalbuphine and Bupivacaine 0.5% with Nalbuphine in Spinal Anaesthesia for Percutaneous Nephrolithotomy.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/054971
Enrollment
80
Registered
2023-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney

Interventions

Intervention1: Group-R: Ropivacaine group: This group will receive single dose of 3.2 ml 0.75% Ropivacaine (heavy) + 2mg Nalbuphine in spinal anaesthesia undergoing Percutaneous Nephrolithotomy (PNCL)

Sponsors

North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing elective PCNL ASA physical status I & II

Exclusion criteria

Exclusion criteria: Patient’s refusal Patient with known allergy to the drugs used in the study Hemodynamic instability. Coagulopathy Patients with significant cardiac, respiratory and hepatic dysfunction • Spinal deformity • Local infection at injection site

Design outcomes

Primary

MeasureTime frame
To compare the onset, duration and intensity of spinal anaesthesia as well as duration of postoperative pain relief.Timepoint: Intraoperative and 24hrs postoperative—

Secondary

MeasureTime frame
Intraoperative hemodynamic changes and incidence of complications.Timepoint: Intra-operative—

Countries

India

Contacts

Public ContactPriyanka Dev

North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences

aggarwalsunny87@gmail.com08259064008

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026